Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes

Clinical Biochemistry

Volumn 42, Issue 7-8, 2009, Pages 562-569

  Han, Yingchun ^a   Randell, Edward ^a   Vasdev, Sudesh ^a   Gill, Vicki ^a   Curran, Matthew ^a   Newhook, Leigh Anne ^a   Grant, Marie ^b   Hagerty, Donna ^b   Schneider, Celine ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Eastern Health Canada   (Canada)

Author keywords

Advanced glycation end product; Hemoglobin A1C; Mass spectrometry; Methylglyoxal; Methylglyoxal derived hydroimidazolone; Solid phase extraction; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; METHYLGLYOXAL;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ADOLESCENT; CHILD; CHROMATOGRAPHY, LIQUID; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 63649138667     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.12.016     Document Type: Article

References (36)

1. International Diabetes Federation. Diabetes prevalence. http://www.idf.org/home/index.cfm?node=264## Accessed 12/18/2008, 2008.
2. World Health Organization. Diabetes, fact sheet no.312. http://www.who.int/mediacentre/factsheets/fs312/en/print.html Accessed 10/2/2008, 2008.
3. Misselwitz J., Franke S., Kauf E., John U., and Stein G. Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr. Nephrol. 17 5 (2002) 316-321
4. Lieuw-A-Fa M.L., van Hinsbergh V.W., Teerlink T., et al. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol. Dial. Transplant. 19 3 (2004) 631-636
5. Hwang J.S., Shin C.H., and Yang S.W. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes. Metab. 7 3 (2005) 263-267
6. Dost A., Klinkert C., Kapellen T., et al. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. Diabetes Care 31 4 (2008) 720-725
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 14 (1993) 977-986
8. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT skin collagen ancillary study group. diabetes control and complications trial. Diabetes 48 4 (1999) 870-880
9. Karachalias N., Babaei-Jadidi R., Ahmed N., and Thornalley P.J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 31 Pt 6 (2003) 1423-1425
10. Fosmark DS, Berg JP, Jensen AB, et al. Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmol in press [Electronic publication ahead of print]. doi:10.111/j.1755-3768.2008.01300x.
11. Mostafa A.A., Randell E.W., Vasdev S.C., et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol. Cell. Biochem. 302 1-2 (2007) 35-42
12. Goh S.Y., and Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93 4 (2008) 1143-1152
13. Jia X., Olson D.J., Ross A.R., and Wu L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J. 20 9 (2006) 1555-1557
14. Park Y.S., Koh Y.H., Takahashi M., et al. Identification of the binding site of methylglyoxal on glutathione peroxidase: methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites arg 184 and 185. Free Radic. Res. 37 2 (2003) 205-211
15. Bidasee K.R., Nallani K., Yu Y., et al. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52 7 (2003) 1825-1836
16. Ahmed N., and Thornalley P.J. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann. N. Y. Acad. Sci. (2005) 1043260-1043266
17. Koide T., Takahara Y., Asada S., and Nagata K. Xaa-arg-gly triplets in the collagen triple helix are dominant binding sites for the molecular chaperone HSP47. J. Biol. Chem. 277 8 (2002) 6178-6182
18. Champe P.C., Harvey R.A., and Ferrier D.R. Fibrous proteins. In: Harvey R.A., and Champe P.C. (Eds). Lippincott's illustrated reviews: biochemistry. 3rd ed. (2005), Philadephia, PA, USA, Lippincott Williams and Wilkins 43-49
19. Thornalley P.J., Battah S., Ahmed N., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375 Pt 3 (2003) 581-592
20. Pruess M., Fleischmann W., Kanapin A., et al. The proteome analysis database: a tool for the in silico analysis of whole proteomes. Nucleic Acids Res. 31 1 (2003) 414-417
21. Fosmark D.S., Torjesen P.A., Kilhovd B.K., et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55 2 (2006) 232-236
22. Ahmed N., Argirov O.K., Minhas H.S., Cordeiro C.A., and Thornalley P.J. Assay of advanced glycation endproducts (AGEs): Surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to nepsilon-carboxymethyl-lysine- and nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem. J. 364 Pt 1 (2002) 1-14
23. Clinical Practice Guidelines Expert Committee of Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 27 Suppl 2 (2003) S1-152
24. Han Y., Randell E., Vasdev S., et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with type 1 diabetes. Mol. Cell. Biochem. 305 1-2 (2007) 123-131
25. Ahmed N., Babaei-Jadidi R., Howell S.K., Thornalley P.J., and Beisswenger P.J. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28 10 (2005) 2465-2471
26. Koschinsky T., He C.J., Mitsuhashi T., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 94 12 (1997) 6474-6479
27. Beisswenger P.J., Howell S.K., Touchette A.D., Lal S., and Szwergold B.S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48 1 (1999) 198-202
28. Mentink C.J., Kilhovd B.K., Rondas-Colbers G.J., Torjesen P.A., and Wolffenbuttel B.H. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth. J. Med. 64 1 (2006) 10-16
29. Likidlilid A., Patchanans N., Poldee S., and Peerapatdit T. Glutathione and glutathione peroxidase in type 1 diabetic patients. J. Med. Assoc. Thai. 90 9 (2007) 1759-1767
30. Thornalley P.J. The glyoxalase system in health and disease. Mol. Aspects Med. 14 4 (1993) 287-371
31. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143 6 (1993) 1699-1712
32. Koka V., Wang W., Huang X.R., Kim-Mitsuyama S., Truong L.D., and Lan H.Y. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 113 10 (2006) 1353-1360
33. Mamputu J.C., and Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes. Metab. 6 2 (2004) 95-103
34. Gu L., Hagiwara S., Fan Q., et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 21 2 (2006) 299-313
35. Gao X., Zhang H., Schmidt A.M., and Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295 2 (2008) H491-498
36. Yeh C.H., Sturgis L., Haidacher J., et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50 6 (2001) 1495-1504